BIIE 0246: Precision Neuropeptide Y Y2 Receptor Antagonist W

2026-04-20

BIIE 0246: Applied Workflows for Neuropeptide Y Y2 Receptor Antagonism

Principle and Setup: Mechanistic Precision in NPY Y2R Inhibition

BIIE 0246 is a potent and selective neuropeptide Y Y2 receptor antagonist, optimized for dissecting the multifaceted roles of NPY signaling in neural, metabolic, and emerging cardiovascular research. With an IC₅₀ of 3.3 nM and Ki values from 8–15 nM at PYY_3-36 binding sites (source: product_spec), BIIE 0246 is uniquely positioned for high-sensitivity studies targeting presynaptic inhibitory effect blockade and modulation of feeding behavior. Its nanomolar affinity and specificity have been validated in both in vitro and in vivo paradigms, including hippocampal slice electrophysiology and behavioral assays (source: reference_article).

Researchers leverage BIIE 0246 for:

Quantifying NPY Y2 receptor inhibition in neuronal circuits.
Decoupling Y2R-mediated presynaptic modulation from Y1/Y5 signaling.
Investigating feeding behavior and anxiolytic responses.

APExBIO supplies BIIE 0246 in a stable, white solid form (MW: 896.06, C₄₉H₅₇N₁₁O₆), with robust solubility in DMSO (up to 67.2 mg/ml) and ethanol (23.55 mg/ml) (source: product_spec).

Step-by-Step Workflow: Enhancing Experimental Rigor

Integrating BIIE 0246 into experimental protocols allows for precise interrogation of Y2R function. Below is a stepwise approach, emphasizing best practices and critical controls.

Compound Preparation: Dissolve BIIE 0246 in DMSO at a stock concentration of 10 mM. Filter-sterilize and store aliquots at 4°C, avoiding freeze-thaw cycles (source: product_spec).
In Vitro Application: For hippocampal slice electrophysiology, pre-incubate slices with 100 nM BIIE 0246 for 20–30 minutes before NPY challenge. This ensures full receptor occupancy and robust blockade (source: reference_article).
In Vivo Studies: For feeding behavior modulation, administer 0.5–3 mg/kg BIIE 0246 intraperitoneally to rats, 30 minutes prior to PYY_3-36 or NPY agonist exposure. Monitor food intake over a 1–4 hour window (source: reference_article).
Behavioral Assays: Use the elevated plus-maze to assess anxiolytic-like effects, ensuring parallel saline and vehicle controls for robust interpretation (source: reference_article).

Protocol Parameters

Electrophysiology (rat hippocampal slices) | 100 nM BIIE 0246 (final) | in vitro NPY Y2R blockade | Achieves full suppression of NPY-induced EPSP inhibition | reference_article
In vivo feeding assay (rat) | 1 mg/kg IP injection | modulation of post-prandial satiety | Validated to reverse PYY_3-36-induced hypophagia | reference_article
Compound solubilization | 10 mM in DMSO, aliquot, store at 4°C | all applications | Prevents potency loss from freeze-thaw; ensures reproducibility | product_spec

Advanced Applications and Comparative Advantages

BIIE 0246 has catalyzed significant advances across neuroscience, metabolic, and, more recently, cardiac domains. Its selectivity for Y2R enables:

Dissection of Presynaptic Inhibitory Networks: By blocking Y2R, researchers can parse NPY’s differential effects on excitatory synaptic transmission without confounding Y1/Y5 interference (source: reference_article).
Feeding and Satiety Pathway Mapping: BIIE 0246’s ability to reverse PYY_3-36-induced anorexia in rodents underpins its value for obesity and appetite research (source: reference_article).
Anxiolytic-like Effect in Elevated Plus-Maze: Acute BIIE 0246 administration enhances open-arm exploration, supporting its utility in anxiety pathway studies (source: reference_article).
Emerging Cardiometabolic Insights: As detailed in the reference study below, NPY signaling in the adipose-neural axis is implicated in cardiac arrhythmogenesis, spotlighting new translational potential for Y2R antagonists (source: Fan et al., 2024).

Compared to less selective inhibitors, BIIE 0246 offers superior interpretability and minimizes off-target effects—critical for mechanistic studies and high-throughput screening (source: reference_article).

Key Innovation from the Reference Study

The recent work by Fan et al. (2024 Cell Reports Medicine) introduced a stem cell-based coculture model integrating sympathetic neurons, cardiomyocytes, and adipocytes to simulate the cardiac microenvironment. The study elucidates how adipocyte-derived leptin activates sympathetic neurons, increasing NPY release, which then exacerbates arrhythmogenic signaling via Y1 receptors and downstream effectors.

While the study’s pharmacological interventions targeted Y1R, NCX, and CaMKII, the findings highlight the broader therapeutic potential of modulating the NPY axis. For experimentalists, this model suggests practical avenues for deploying BIIE 0246:

Use in coculture systems to parse Y2R-specific NPY effects versus Y1R-driven mechanisms.
Screening for cross-talk between metabolic (adipocyte) and neural (sympathetic) compartments using selective Y2 antagonism.
Evaluating BIIE 0246 alongside Y1R inhibitors to understand compensatory or synergistic receptor dynamics in cardiac and neural tissues.

Troubleshooting and Optimization Tips

Compound Stability: Prepare fresh working solutions for each experiment; long-term storage of diluted BIIE 0246, especially in aqueous buffers, leads to potency loss (source: product_spec).
Vehicle Controls: Always include DMSO (≤0.1%) or ethanol-only controls to rule out solvent effects on cell viability and behavioral outcomes.
Concentration Titration: Pilot a concentration range (1–100 nM in vitro; 0.5–3 mg/kg in vivo) to define the minimal efficacious dose for your assay and minimize off-target activity (source: workflow_recommendation).
Assay Timing: Ensure preincubation (at least 20 minutes) before NPY/PYY analog addition in slice or cell systems to secure full receptor blockade (source: reference_article).
Batch Consistency: Use the same APExBIO lot for all replicates in a study to avoid batch-specific variability (source: workflow_recommendation).

Interlinking Related Resources

BIIE 0246: Advancing NPY Y2R Antagonism for Neurocardiac Research complements this workflow by providing a deeper exploration of neurocardiac and metabolic regulation via NPY Y2R antagonism.
BIIE 0246: Decoding Neuropeptide Y Y2 Receptor Antagonism extends the content here with a unique focus on adipose-neural axis and translational feeding behavior research.
BIIE 0246 (SKU B6836): Precision Y2 Receptor Antagonism contrasts workflow strategies for cell viability and cytotoxicity assays using BIIE 0246.

Why this Cross-Domain Matters, Maturity, and Limitations

The emerging connection between NPY signaling and cardiac arrhythmias, as shown in the referenced study, opens a new avenue for BIIE 0246 in cardiometabolic research. While current literature predominantly explores Y1R as the arrhythmogenic mediator, the established role of Y2R in presynaptic modulation suggests that Y2 antagonism may reveal new mechanistic insights within coculture or in vivo models of the adipose-neural axis (source: Fan et al., 2024). However, direct evidence for Y2R antagonists modulating arrhythmia outcomes remains to be established; thus, such applications are still exploratory (source: workflow_recommendation).

Future Outlook

Continued deployment of BIIE 0246—especially in advanced multicellular platforms and in vivo models—will clarify the role of selective Y2 receptor antagonism in neurocardiac, metabolic, and behavioral phenotypes. The referenced stem cell-based coculture model sets the stage for mechanistic dissection of how NPY subtypes and receptor crosstalk drive pathology. As APExBIO continues to deliver high-purity BIIE 0246, the compound’s utility is poised to expand into new domains, pending rigorous bench-to-bedside validation (source: Fan et al., 2024).

For more details and ordering, visit the BIIE 0246 product page.